BridgeBio Pharma, Inc. Loans Payable, Noncurrent
BridgeBio Pharma, Inc. (BBIO) had Loans Payable, Noncurrent of $422.97 million as of 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt and Lease Obligation
us-gaap:LongTermLoansPayable · last filed 2022-11-03
- 2022-09-30: Loans Payable, Noncurrent $422.97M.
- 2022-06-30: Loans Payable, Noncurrent $418.35M.
- 2021-12-31: Loans Payable, Noncurrent $430.75M.
| Period end | Loans Payable, Noncurrent |
|---|---|
| 2022-09-30 | $422.97M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $418.35M 10-Q · filed 2022-08-04 |
| 2021-12-31 | $430.75M 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |